We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

56 hedge funds and large institutions have $295M invested in Kiniksa Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

520% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 5

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

8.41% more ownership

Funds ownership: 79.15% → 87.56% (+8.4%)

8% more funds holding

Funds holding: 52 → 56 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

24% less capital invested

Capital invested by funds: $385M → $295M (-$90.6M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
31
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
+$31.1M
2
VC
Vivo Capital
California
+$11.2M
3
HA
HHLR Advisors
Cayman Islands
+$8.63M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.53M
5
BlackRock
BlackRock
New York
+$6.24M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$10.8M
2
Millennium Management
Millennium Management
New York
-$1.46M
3
Invesco
Invesco
Georgia
-$1.25M
4
AG
Algert Global
California
-$300K
5
AllianceBernstein
AllianceBernstein
Tennessee
-$247K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
26
Foresite Capital Management IV
California
$1.15M – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$848K +$509K +26,374 +128%
AA
28
ALPS Advisors
Colorado
$805K +$157K +8,115 +22%
Morgan Stanley
29
Morgan Stanley
New York
$703K +$286K +14,808 +61%
First Manhattan
30
First Manhattan
New York
$686K +$734K +38,000 +633,333%
Millennium Management
31
Millennium Management
New York
$561K -$1.46M -75,336 -71%
PPA
32
Parametric Portfolio Associates
Washington
$484K +$82K +4,243 +19%
Squarepoint
33
Squarepoint
New York
$479K +$228K +11,788 +80%
Charles Schwab
34
Charles Schwab
California
$434K +$176K +9,092 +61%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$332K +$165K +8,558 +87%
Goldman Sachs
36
Goldman Sachs
New York
$315K +$337K +17,469 New
TA
37
Teachers Advisors
New York
$299K +$157K +8,107 +96%
Deutsche Bank
38
Deutsche Bank
Germany
$246K +$131K +6,783 +97%
Wells Fargo
39
Wells Fargo
California
$244K +$73.2K +3,787 +39%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$231K +$93.9K +4,862 +61%
VEA
41
Virtus ETF Advisers
New York
$212K -$34.2K -1,773 -13%
TCIM
42
TIAA CREF Investment Management
New York
$182K +$37.2K +1,924 +24%
AIG
43
American International Group
New York
$137K +$63.5K +3,288 +77%
SO
44
STRS Ohio
Ohio
$88K – – –
Barclays
45
Barclays
United Kingdom
$80K +$25.3K +1,311 +43%
Bank of America
46
Bank of America
North Carolina
$74K -$146K -7,542 -65%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$69K – – –
Citigroup
48
Citigroup
New York
$62K +$39.3K +2,033 +146%
JP Morgan Chase
49
JP Morgan Chase
New York
$52K +$23.6K +1,222 +74%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$48.5K +$47.7K +2,467 +1,132%
1
2
3

KNSA Hedge Fund Activity: Q1 2019 in Review

56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2019, worth a combined $295M — down 24% from $385M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new KNSA positions and 5 closed out — a net gain of 4 holders — while 31 added to existing stakes and 5 trimmed.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $31.1M. The largest seller was Cormorant Asset Management, cutting an estimated $10.8M.

  • 56 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2019, up from 52 in Q4 2018.
  • Funds reported $295M of Kiniksa Pharmaceuticals stock for Q1 2019, down 24% quarter-over-quarter.
  • 9 funds opened new Kiniksa Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +4 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q1 2019 was ArrowMark Colorado Holdings, an estimated $31.1M added.
  • The largest Kiniksa Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q1 2019.